Takeda to Use Zinfandel TOMM40 Biomarker Assay for Alzheimer's Drug Study | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) - Takeda Pharmaceutical Company will use a biomarker assay developed by Zinfandel Pharmaceuticals as part of a clinical trial investigating the utility of Takeda's drug Actos in Alzheimer's disease, the companies said this week.

Under the terms of the agreement, Takeda has taken an exclusive, worldwide license for the use of Zinfandel's TOMM40 assay as a biomarker for the risk of Alzheimer's disease in high-risk older adults with normal cognition.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: genetic analysis of pollutant-tolerant fish, and more.

Researchers have found a rare carbapenem resistance gene on a US pig farm, NBC News reports.

New York officials are considering the use of a familial DNA search to get a lead on a suspect in the strangulation death of a runner.

NIH Director Francis Collins has selected a retired Army major general and cardiologist for the CEO spot at the agency's embattled Clinical Center.